BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BBIO BridgeBio Pharma, Inc.

休市中 12-12 16:00:00 EST

75.15

+1.09

+1.46%

盘后74.67

-0.48-0.64%

19:39 EST

最高75.24	最低72.65	成交量159.72万
今开73.83	昨收74.07	日振幅3.50%
总市值144.82亿	流通市值113.63亿	总股本1.93亿
成交额1.19亿	换手率1.06%	流通股本1.51亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BBIO","market":"US","secType":"STK","nameCN":"BridgeBio Pharma, Inc.","latestPrice":75.15,"timestamp":1765573200000,"preClose":74.065,"halted":0,"volume":1597227,"hourTrading":{"tag":"盘后","latestPrice":74.67,"preClose":75.15,"latestTime":"19:39 EST","volume":39729,"amount":2985329.7196,"timestamp":1765586347941},"delay":0,"floatShares":151204231,"shares":192708813,"eps":-4.18436,"marketStatus":"休市中","change":1.085,"latestTime":"12-12 16:00:00 EST","open":73.83,"high":75.24,"low":72.65,"amount":119052964.108695,"amplitude":0.034969,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.18436,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1561608000000,"exchange":"NASDAQ","adjPreClose":74.065,"preHourTrading":{"tag":"盘前","latestPrice":73.2,"preClose":74.065,"latestTime":"09:27 EST","volume":150,"amount":11058.6456,"timestamp":1765549654708},"postHourTrading":{"tag":"盘后","latestPrice":74.67,"preClose":75.15,"latestTime":"19:39 EST","volume":39729,"amount":2985329.7196,"timestamp":1765586347941},"volumeRatio":0.9264042901299799,"impliedVol":0.5326,"impliedVolPercentile":0.332},"requestUrl":"/m/hq/s/BBIO","defaultTab":"news","newsList":[{"id":"2579414433","title":"Bridgebio Pharma, Inc.盘中异动 快速跳水5.00%报63.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579414433","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579414433?lang=zh_cn&edition=full","pubTime":"2025-10-30 22:28","pubTimestamp":1761834497,"startTime":"0","endTime":"0","summary":"北京时间2025年10月30日22时28分，Bridgebio Pharma, Inc.股票出现波动，股价快速下跌5.00%。Bridgebio Pharma, Inc.股票所在的生物技术行业中，整体跌幅为0.64%。Bridgebio Pharma, Inc.公司简介：BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。消息层面，截至22时28分，《H.C. Wainwright维持BridgeBio Pharma买入评级，上调目标价至90美元》资讯为影响Bridgebio Pharma, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103022281894e5b837&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025103022281894e5b837&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4505","BBIO","BK4139"],"gpt_icon":0},{"id":"1127410741","title":"BridgeBio公布Encaleret在常染色体显性低钙血症1型患者中积极的三期顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1127410741","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127410741?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:22","pubTimestamp":1761736957,"startTime":"0","endTime":"0","summary":"10月29日 - BridgeBio Pharma, Inc.公告称：*BRIDGEBIO公布Encaleret在常染色体显性低钙血症1型患者中的积极三期顶线结果*BRIDGEBIO PHARMA INC：CALIBRATE研究显示Encaleret在ADH1患者中满足所有预设的主要和关键次要疗效终点*BRIDGEBIO PHARMA INC：计划于2026年启动Encaleret在慢性甲状旁腺功能减退症和儿科ADH1中的注册研究*BRIDGEBIO PHARMA INC：Encaleret耐受良好，研究药物未出现相关停药情况*BRIDGEBIO PHARMA INC - 76%的Encaleret参与者达到了目标钙水平*BRIDGEBIO PHARMA INC - 91%的Encaleret参与者的PTH水平超过参考范围*BRIDGEBIO PHARMA INC - 计划在2026年上半年提交新药申请","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BK4505","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"1180574253","title":"BridgeBio Pharma, Inc.：计划于2026年启动Encaleret在慢性甲状旁腺功能减退症和儿童Adh1中的注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1180574253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180574253?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:03","pubTimestamp":1761735789,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma, Inc.：计划于2026年启动Encaleret在慢性甲状旁腺功能减退症和儿童Adh1中的注册研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBIO","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"1142199915","title":"异动解读 | BridgeBio盘前大涨5.16%，Encaleret药物三期试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1142199915","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142199915?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:02","pubTimestamp":1761735750,"startTime":"0","endTime":"0","summary":"周三盘前，生物制药公司BridgeBio Pharma, Inc.股价大涨5.16%，引发市场关注。根据公司最新发布的消息，BridgeBio的重磅药物Encaleret在自体显性低钙血症1型患者中进行的第三阶段临床试验中取得了积极的顶线结果。自体显性低钙血症1型是一种罕见的遗传性疾病，目前尚无获批的针对性治疗方法。Encaleret的成功将为ADH1患者带来新的治疗希望，同时也有望为BridgeBio带来可观的市场机会。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"gpt_icon":0},{"id":"1158197019","title":"BridgeBio发布Encaleret在自体显性低钙血症1型患者中取得积极的第三阶段顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1158197019","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158197019?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:00","pubTimestamp":1761735651,"startTime":"0","endTime":"0","summary":"BridgeBio发布Encaleret在自体显性低钙血症1型患者中取得积极的第三阶段顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BBIO","BK4588","BK4505","BK4585"],"gpt_icon":0},{"id":"1163832932","title":"Acoramidis在ATTR-CM患者治疗的第一个月内开始减少累积心血管不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1163832932","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163832932?lang=zh_cn&edition=full","pubTime":"2025-09-28 23:18","pubTimestamp":1759072707,"startTime":"0","endTime":"0","summary":"Acoramidis在ATTR-CM患者治疗的第一个月内开始减少累积心血管不良事件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BBIO","BK4139","BK4588","BK4505"],"gpt_icon":0},{"id":"2566943391","title":"BridgeBio(BBIO.US)指控辉瑞(PFE.US)、Alnylam(ALNY.US)在数十亿美元心脏病药市场采用“争议策略”竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2566943391","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566943391?lang=zh_cn&edition=full","pubTime":"2025-09-12 08:27","pubTimestamp":1757636836,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，BridgeBio Pharma正凭借一款心脏病药物与辉瑞、Alnylam Pharmaceuticals展开竞争。该公司称其药物疗效更优且成本更低，但同时指控竞争对手在这个价值数十亿美元的市场中采用“有争议的策略”进行竞争。BridgeBio表示，其研发的药物Attruby拥有充分的科学数据支持，足以成为该疾病的“标准治疗方案”，但市场竞争的激烈程度远超预期。库马尔则称，BridgeBio已就辉瑞的推广行为向OPDP提交信函，但尚未看到该机构采取行动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0456855351.SGD","BK4599","LU1883839398.USD","IE00B19Z3B42.SGD","LU0868494617.USD","PFE","BK4007","SG9999003800.SGD","LU1894683348.USD","LU0321505868.SGD","LU0058720904.USD","BK4505","LU0320765992.SGD","BK4548","IE0002270589.USD","LU1057294990.SGD","LU1066051498.USD","SG9999001176.USD","BK4588","BK4568","IE00BBT3K403.USD","LU0225284248.USD","BK4534","LU0321505439.SGD","SG9999011175.SGD","LU0234572021.USD","BBIO","BK4139","LU0889565916.HKD","LU1066053197.SGD","ALNY","BK4592","BK4585","IE00BLSP4239.USD","LU0225771236.USD","SGXZ57979304.SGD","LU0985481810.HKD","SG9999013999.USD","LU1023059063.AUD","SG9999002232.USD","LU1894683264.USD","LU0170899867.USD","SG9999001176.SGD","SG9999002224.SGD","LU0306806265.USD","IE00BLSP4452.SGD","BK4581","LU0289739699.SGD","LU0109394709.USD","LU0306807586.USD"],"gpt_icon":0},{"id":"1184773540","title":"BridgeBio Pharma Inc - Encaleret药物耐受性良好，研究期间未报告严重不良事件","url":"https://stock-news.laohu8.com/highlight/detail?id=1184773540","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184773540?lang=zh_cn&edition=full","pubTime":"2025-09-07 02:32","pubTimestamp":1757183555,"startTime":"0","endTime":"0","summary":"BridgeBio Pharma Inc宣布，其药物Encaleret在研究期间表现出良好的耐受性，未报告严重不良事件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBIO","BK4505","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"1144611085","title":"Acoramidis在ATTRIBUTE-CM开放标签扩展研究第42个月时显示心血管死亡率显著统计学降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1144611085","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144611085?lang=zh_cn&edition=full","pubTime":"2025-08-30 19:16","pubTimestamp":1756552581,"startTime":"0","endTime":"0","summary":"Acoramidis在ATTRIBUTE-CM开放标签扩展研究第42个月时显示心血管死亡率显著统计学降低","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","BK4585","BBIO","BK4588"],"gpt_icon":0},{"id":"2558692379","title":"Bridgebio Pharma, Inc.8月11日成交额为1.12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558692379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558692379?lang=zh_cn&edition=full","pubTime":"2025-08-12 09:22","pubTimestamp":1754961742,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日，Bridgebio Pharma, Inc.成交额为1.12亿美元，成交额较昨日减少6.30%，当日成交量为233.56万股。Bridgebio Pharma, Inc.于2025年8月11日涨3.56%，报48.24美元，该股过去5个交易日涨1.03%，年初至今涨75.8%，过去60日涨43.32%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-11|1.12亿|-6.30%|233.56万|#|2025-08-08|1.19亿|-1.62%|257.02万|#|2025-08-07|1.21亿|-80.42%|266.23万|#|2025-08-06|6.19亿|122.90%|1410.82万|#|2025-08-05|2.78亿|134.16%|569.09万|BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812092231a482e515&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812092231a482e515&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4139","BK4588","BK4585","BK4505"],"gpt_icon":0},{"id":"2558211681","title":"Bridgebio Pharma, Inc.2025财年第二财季实现净利润-1.82亿美元，同比减少147.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558211681","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558211681?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841698,"startTime":"0","endTime":"0","summary":"8月11日，Bridgebio Pharma, Inc.公布财报，公告显示公司2025财年第二财季净利润为-1.82亿美元，同比减少147.75%；其中营业收入为1.11亿美元，同比增加5015.21%，每股基本收益为-0.95美元。从资产负债表来看，Bridgebio Pharma, Inc.总负债28.59亿美元，其中短期债务9.59百万美元，资产负债比为0.38，流动比率为5.19。机构评级：截至2025年8月11日，当前有20家机构对Bridgebio Pharma, Inc.目标价做出预测，其中目标均价为63.20美元，其中最低目标价为42.00美元，最高目标价为95.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000402a48057c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000402a48057c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO"],"gpt_icon":0},{"id":"2558503163","title":"Bridgebio Pharma, Inc.8月8日成交额为1.19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558503163","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558503163?lang=zh_cn&edition=full","pubTime":"2025-08-09 09:22","pubTimestamp":1754702544,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日，Bridgebio Pharma, Inc.成交额为1.19亿美元，成交额较昨日减少1.62%，当日成交量为257.02万股。Bridgebio Pharma, Inc.于2025年8月8日涨1.37%，报46.58美元，该股过去5个交易日跌1.67%，年初至今涨69.75%，过去60日涨40.05%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-08|1.19亿|-1.62%|257.02万|#|2025-08-07|1.21亿|-80.42%|266.23万|#|2025-08-06|6.19亿|122.90%|1410.82万|#|2025-08-05|2.78亿|134.16%|569.09万|#|2025-08-04|1.19亿|13.26%|248.85万|BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809092235a47e1d99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809092235a47e1d99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BBIO","BK4588","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2557516108","title":"Bridgebio Pharma, Inc.8月7日成交额为1.21亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557516108","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557516108?lang=zh_cn&edition=full","pubTime":"2025-08-08 09:22","pubTimestamp":1754616142,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日，Bridgebio Pharma, Inc.成交额为1.21亿美元，成交额较昨日减少80.42%，当日成交量为266.23万股。Bridgebio Pharma, Inc.于2025年8月7日涨2.54%，报45.95美元，该股过去5个交易日跌2.79%，年初至今涨67.46%，过去60日涨28.78%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-07|1.21亿|-80.42%|266.23万|#|2025-08-06|6.19亿|122.90%|1410.82万|#|2025-08-05|2.78亿|134.16%|569.09万|#|2025-08-04|1.19亿|13.26%|248.85万|#|2025-08-01|1.05亿|-21.52%|221.56万|BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808092228a6d9cde6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808092228a6d9cde6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4588","BBIO","BK4585","BK4139"],"gpt_icon":0},{"id":"2557814115","title":"Bridgebio Pharma, Inc.8月6日成交额为6.19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557814115","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557814115?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:21","pubTimestamp":1754529716,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日，Bridgebio Pharma, Inc.成交额为6.19亿美元，成交额较昨日增加122.90%，当日成交量为1410.82万股。Bridgebio Pharma, Inc.于2025年8月6日跌8.94%，报44.81美元，该股过去5个交易日跌1.78%，年初至今涨63.3%，过去60日涨31.14%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-06|6.19亿|122.90%|1410.82万|#|2025-08-05|2.78亿|134.16%|569.09万|#|2025-08-04|1.19亿|13.26%|248.85万|#|2025-08-01|1.05亿|-21.52%|221.56万|#|2025-07-31|1.33亿|72.95%|282.08万|BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807092203a479b54d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807092203a479b54d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4585","BK4588","BK4139","BBIO"],"gpt_icon":0},{"id":"1142390528","title":"异动解读 | BridgeBio Pharma盘中大跌11.93%，季度亏损超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1142390528","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142390528?lang=zh_cn&edition=full","pubTime":"2025-08-06 22:01","pubTimestamp":1754488903,"startTime":"0","endTime":"0","summary":"生物制药公司BridgeBio Pharma今日盘中大跌11.93%，引发市场关注。这一跌势主要源于公司公布的季度业绩未能达到分析师预期。根据公司最新发布的财报，截至6月30日的季度中，BridgeBio Pharma调整后每股亏损为0.95美元，高于分析师平均预期的0.84美元亏损。值得注意的是，在此次财报公布之前，BridgeBio Pharma的股价表现相当强劲。过去一个季度，公司股价上涨了10.6%，今年迄今为止更是上涨了74.0%。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"gpt_icon":0},{"id":"1169912494","title":"异动解读 | BridgeBio Pharma盘前大跌11.40%，季度业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1169912494","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169912494?lang=zh_cn&edition=full","pubTime":"2025-08-06 17:40","pubTimestamp":1754473247,"startTime":"0","endTime":"0","summary":"生物制药公司BridgeBio Pharma今日盘前股价大跌11.40%，主要原因是该公司公布的季度业绩未能达到分析师预期。根据公司发布的财报，截至6月30日的季度中，BridgeBio Pharma调整后每股亏损为0.95美元，高于分析师平均预期的0.84美元亏损。该季度公司净亏损高达1.819亿美元。值得注意的是，在此次财报公布之前，BridgeBio Pharma的股价表现相当强劲。过去一个季度，公司股价上涨了10.6%，今年迄今为止更是上涨了74.0%。尽管本次业绩不及预期，但华尔街分析师对公司前景仍保持乐观态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"gpt_icon":0},{"id":"2557345769","title":"Bridgebio Pharma, Inc.8月5日成交额为2.78亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557345769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557345769?lang=zh_cn&edition=full","pubTime":"2025-08-06 09:21","pubTimestamp":1754443300,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日，Bridgebio Pharma, Inc.成交额为2.78亿美元，成交额较昨日增加134.16%，当日成交量为569.09万股。Bridgebio Pharma, Inc.于2025年8月5日涨3.06%，报49.21美元，该股过去5个交易日涨6.24%，年初至今涨79.34%，过去60日涨41.21%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-05|2.78亿|134.16%|569.09万|#|2025-08-04|1.19亿|13.26%|248.85万|#|2025-08-01|1.05亿|-21.52%|221.56万|#|2025-07-31|1.33亿|72.95%|282.08万|#|2025-07-30|7717.69万|13.93%|168.36万|BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806092147a4778bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806092147a4778bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BBIO","BK4588","BK4585","BK4505"],"gpt_icon":0},{"id":"1129759925","title":"异动解读 | BridgeBio Pharma股价夜盘大跌14.06%，季度业绩不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1129759925","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129759925?lang=zh_cn&edition=full","pubTime":"2025-08-06 08:13","pubTimestamp":1754439183,"startTime":"0","endTime":"0","summary":"生物制药公司BridgeBio Pharma今日夜盘股价大跌14.06%，主要原因是该公司公布的季度业绩未能达到分析师预期。根据公司发布的财报，截至6月30日的季度中，BridgeBio Pharma调整后每股亏损为0.95美元，高于分析师平均预期的0.84美元亏损。该季度公司净亏损高达1.819亿美元。值得注意的是，在此次财报公布之前，BridgeBio Pharma的股价表现相当强劲。过去一个季度，公司股价上涨了10.6%，今年迄今为止更是上涨了74.0%。尽管本次业绩不及预期，但华尔街分析师对公司前景仍保持乐观态度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"gpt_icon":0},{"id":"1189704125","title":"异动解读 | 业绩不及预期，BridgeBio Pharma盘后暴跌12.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1189704125","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189704125?lang=zh_cn&edition=full","pubTime":"2025-08-06 05:23","pubTimestamp":1754429017,"startTime":"0","endTime":"0","summary":"周二盘后交易中，生物制药公司BridgeBio Pharma股价大跌12.42%，主要原因是该公司公布的季度业绩未能达到分析师预期。根据公司发布的财报，截至6月30日的季度中，BridgeBio Pharma调整后每股亏损为0.95美元，高于分析师平均预期的0.84美元亏损。值得注意的是，在此次财报公布之前，BridgeBio Pharma的股价表现相当强劲。过去一个季度，公司股价上涨了10.6%，今年迄今为止更是上涨了74.0%。尽管本次业绩不及预期，但华尔街分析师对公司前景仍保持乐观态度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BBIO"],"gpt_icon":0},{"id":"2557355838","title":"Bridgebio Pharma, Inc.8月4日成交额为1.19亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557355838","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557355838?lang=zh_cn&edition=full","pubTime":"2025-08-05 09:21","pubTimestamp":1754356886,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日，Bridgebio Pharma, Inc.成交额为1.19亿美元，成交额较昨日增加13.26%，当日成交量为248.85万股。Bridgebio Pharma, Inc.于2025年8月4日涨0.8%，报47.75美元，该股过去5个交易日涨3.29%，年初至今涨74.02%，过去60日涨33.31%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-08-04|1.19亿|13.26%|248.85万|#|2025-08-01|1.05亿|-21.52%|221.56万|#|2025-07-31|1.33亿|72.95%|282.08万|#|2025-07-30|7717.69万|13.93%|168.36万|#|2025-07-29|6774.05万|-28.96%|146.20万|BridgeBio Pharma是一家生物技术公司，专注于发现、开发、测试和提供针对遗传疾病患者的变革性治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805092134a6d35658&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805092134a6d35658&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BBIO","BK4505","BK4588","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bridgebio.com;investor.bridgebio.com","stockEarnings":[{"period":"1week","weight":0.0205},{"period":"1month","weight":0.1349},{"period":"3month","weight":0.4675},{"period":"6month","weight":0.8891},{"period":"1year","weight":1.7159},{"period":"ytd","weight":1.7387}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BridgeBio Pharma, Inc.于2019年5月17日在特拉华州成立。该公司是一家处于商业阶段的生物制药公司，旨在发现、创造、测试和提供具有变革性的药物，以治疗具有明确遗传驱动因素的遗传性疾病和癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052015},{"month":2,"riseRate":0.5,"avgChangeRate":0.034422},{"month":3,"riseRate":0.333333,"avgChangeRate":0.071713},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.072554},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.032997},{"month":6,"riseRate":0.833333,"avgChangeRate":0.148281},{"month":7,"riseRate":0.571429,"avgChangeRate":0.133769},{"month":8,"riseRate":0.714286,"avgChangeRate":0.038877},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.051108},{"month":10,"riseRate":0.714286,"avgChangeRate":0.041692},{"month":11,"riseRate":0.714286,"avgChangeRate":0.102784},{"month":12,"riseRate":0.714286,"avgChangeRate":0.044538}],"exchange":"NASDAQ","name":"BridgeBio Pharma, Inc.","nameEN":"BridgeBio Pharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BridgeBio Pharma, Inc.,BBIO,BridgeBio Pharma, Inc.股票,BridgeBio Pharma, Inc.股票老虎,BridgeBio Pharma, Inc.股票老虎国际,BridgeBio Pharma, Inc.行情,BridgeBio Pharma, Inc.股票行情,BridgeBio Pharma, Inc.股价,BridgeBio Pharma, Inc.股市,BridgeBio Pharma, Inc.股票价格,BridgeBio Pharma, Inc.股票交易,BridgeBio Pharma, Inc.股票购买,BridgeBio Pharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BridgeBio Pharma, Inc.(BBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BridgeBio Pharma, Inc.(BBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}